

| | |
|---|--|
| BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 | National Stock Exchange of India Limited, Listing Department, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 |
| Scrip Code – 530517 | Symbol – RELAXO |

Sub: Newspaper advertisement of the Audited Financial Results for the quarter and financial year ended on March 31, 2026

Dear Madam / Sir,

Pursuant to Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith copies of the Newspaper Advertisement of the Audited Financial Results for the quarter and financial year ended on March 31, 2026 as published in The Economics Times (Mumbai and Delhi – English Edition) and Navbharat Times (Delhi – Hindi Edition) on May 29, 2026.

The same is for your information and records please.

Thanking You,

For Relaxo Footwears Limited,

Ankit Jain
Company Secretary & Compliance Officer

Encl. as above

RELAXO FOOTWEARS LIMITED

Registered Office: Aggarwal City Square, Plot No. 10, Manglam Place,
District Centre, Sector-3, Rohini, Delhi-110085. Phones: 46800 600, 46800 700

Fax: 46800 692 E-mail: rfl@relaxofootwear.com

CIN L74899DL1984PLC019097

Classification: **Public**



ET Q&A **ACHIN GUPTA**
MD & GROUP CEO, CIPLA

'Innovation, Biosimilars, Complex Generics to Drive Cipla's Growth'

Cipla is increasingly focusing on innovation which it expects to account for "a meaningful chunk of revenues" by the time the drug maker reaches its centenary in about 10 years, says managing director and group chief executive Achin Gupta. In an interview, he tells **Rica Bhattacharyya** and **Vikas Dandekar** that the company will look at assets in the US and Europe that can strengthen its market presence and product pipeline, but is not considering any large acquisitions in India. **Edited excerpts:**

How do you see Cipla in the next 10 years? If you look at Cipla's journey over 90 years, there have been phases of growth and diseases we've helped fight against. Respiratory was one such intervention. We led the shift from oral therapies to inhalation in India. Over the years that journey continued with transparent rotahalers, metered dose inhalers, breath-actuated devices, multidose DPIs like Synchrobreath and Ciplhaler, and newer molecules and innovations. HIV was another major crusade, especially in Africa. The 'dollar-a-day' initiative changed the landscape and saved millions of lives. Covid was another phase where supply interventions were very helpful in both India and globally. When we think about 100 years, we want to continue that journey—increasing access while building the business. India will continue to remain our largest market. We are No 1 by volume in India in IQVIA ranking. Respiratory remains a very important area, but we also want to double down on chronic conditions like diabetes, cardiovascular diseases and obesity because these conditions impact a huge population.

What are your global ambitions? North America is our next big market. Historically, we were present more through partnerships, but our direct front-end presence has developed over the last decade. The focus there will be on complex products—respiratory, peptides and oligonucleotides. We have four respiratory products expecting approval this year and another three peptides in the pipeline, including a big one. We plan to file almost 40-50 products globally over the next three years. We have two biosimilars under development for North America, and one is already under IND (investigational new drug) entering Phase 1 studies. Our plan is to add one to two biosimilars every year over the next five to six years so that we build a portfolio of around 10 products. Europe is another region where we are currently

under-indexed relative to the opportunity, and we believe we can scale significantly there.

What role will innovation and AI play in Cipla's next phase of growth? Innovation is the next big thing. That's a five-to-ten-year journey. By the time we reach our centenary, we would definitely want a meaningful chunk of revenues coming from innovation. The mainstay will still be generics—more than 80%. But that will increasingly be supplemented with innovation. We've already started building the blocks through stem cells, mRNA-related work and inhaled insulin. We also want to become an AI-first organisation. AI is already changing productivity and ways of working. The first step is to make all employees AI-literate and then identify processes where AI can make the maximum difference.

How important would acquisitions be as part of your future strategy? Cipla has not been acquisitive in so many years. What we have done so far is smaller partnerships and targeted stuff. In India, large acquisitions are unlikely because we are already number one by volume and there would be too much overlap. So, we will chase quality of business. We would want to go after

WE WOULD want a meaningful chunk of revenues to come from Innovation... We've already started building the blocks through stem cells, mRNA-related work and inhaled insulin



FOR FULL INTERVIEW, GO TO www.economicstimes.com

segments where we see Cipla genuinely fulfilling some need gap. In the US and Europe, however, we would look at differentiated assets because they can strengthen both our market presence and our pipeline.

What are your plans in the cardio-metabolic space and obesity? In India, we've been consistently launching diabetes and cardio products. In cardiology, our biggest brand is Dytol, which has become one of the largest brands in the category. In diabetes, we have launched all the SGLT2 products and partnered to bring in the DPP4 portfolio. We also launched inhaled insulin and made the entire insulin range from Eli Lilly. We've been accelerating in this segment for the last four to five years because we realised the patient population is vast while our presence was relatively smaller. On obesity, we partnered with Lilly because we saw it as the best-in-class molecule. Our focus for Yurpeak (tirzepatide) is beyond the metros, where our presence is deep, and we are seeing steady growth. Semaglutide, for us, is more of an international generic opportunity because the Indian market is becoming very crowded.

Why stay focused on Lilly's tirzepatide rather than semaglutide in India? In this category, the amount of intervention required is significantly higher. It involves patient onboarding, disease management and field-force engagement. We felt it was better not to dilute our efforts. Because tirzepatide is a dual-receptor product, we see it as a bigger opportunity. At the same time, many generic players are entering semaglutide, and prices are already dropping sharply. We are clearly playing in the best-in-class segment rather than the mass market.

Investors appear optimistic about Cipla's long-term growth despite near-term margin pressure. What are they seeing? We had exclusivity on lenalidomide (Revlimid), and that exclusivity has now expired. The dip in profitability (in Q4) was anticipated. We have also invested heavily in alternate manufacturing sites in the US to de-risk our pipeline. Those facilities are ready, so the costs are flowing through before revenues begin. Looking ahead, we have four respiratory launches expected this year, including gVentolin (just happened), gSymbicort and gAdvair.

Wockhardt Receives Regulatory Okay for Superbug Antibiotic

New Delhi: In a significant breakthrough in India's fight against drug-resistant bacterial infections, Wockhardt has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market Zaynich, an indigenously discovered and developed antibiotic, in the country. The drug, a combination of Zidebactam and Cefepime, is the first in its class and has been approved for treating complicated urinary tract infections, including severe kidney infections, in adult patients. —Teena Thacker

Zydus Granted US FDA Priority Review for Liver Disease Drug

Mumbai: The US Food and Drug Administration (FDA) has granted priority review to the new drug application for saroglitazar, Zydus Lifesciences' treatment for primary biliary cholangitis (PBC), a chronic autoimmune liver disease, the company said on Thursday. Zydus Therapeutics on Thursday said that the US FDA has granted priority review to its New Drug Application for saroglitazar, which is used to treat primary biliary cholangitis, an autoimmune disease that gradually destroys the bile ducts in the liver. —Our Bureau

Reliance Industries Limited
Growth is Life

Regd. Office: 3rd Floor, Maker Chambers IV, 222, Nariman Point, Mumbai 400 021
Phone: +91-22-3555 5000 • Fax: +91-22-2204 2268 • E-mail: investor.relations@ril.com
CIN: L17110MH1973PLC019786

NOTICE FOR THE ATTENTION OF MEMBERS OF THE COMPANY FORTY-NINTH ANNUAL GENERAL MEETING (POST-IPO) AND INFORMATION ON E-VOTING

Notice calling the Forty-ninth Annual General Meeting (Post-IPO) ("AGM") of the Company, scheduled to be held in compliance with applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") on Friday, June 19, 2026 at 2:00 P.M. (IST), and the stand-alone and consolidated audited financial statement for the financial year 2025-26, along with Board's Report, Auditors' Report and other documents required to be attached thereto, have been sent on Thursday, May 28, 2026, electronically to the members of the Company. Further, a letter providing the web-link, including the exact path, where Annual Report and the notice of the AGM for the financial year 2025-26 is available, is being sent to those members whose e-mail address is not registered with the Company / KFin Technologies Limited ("KFinTech"). Company's Registrar and Transfer Agent / Depository Participant(s) / Depositories. The Notice of AGM and the Annual Report for the financial year 2025-26 are available on the Company's website at www.ril.com and on the website of the Stock Exchanges, i.e., BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") at www.bseindia.com and www.nseindia.com, respectively, and on the website of KFinTech, at <https://evoting.kfintech.com>.

The documents referred to in the Notice of the AGM are available electronically for inspection, on all working days, by the members from the date of circulation of the Notice of the AGM. Members seeking to inspect such documents can send an e-mail to rilagm@ril.com mentioning his / her / its folio number / DP ID and Client ID.

Remote e-voting and e-voting during AGM:

The Company is providing to its members, facility to exercise their right to vote on resolutions proposed to be passed at AGM by electronic means ("e-voting"). Members may cast their votes remotely on the dates mentioned herein below ("remote e-voting"). The Company has engaged the services of KFinTech as the agency to provide e-voting facility.

Information and instructions comprising manner of voting, including voting remotely by members holding shares in dematerialised mode, physical mode and for members who have not registered their e-mail address has been provided in the Notice of the AGM. The manner in which (a) persons who become members of the Company after despatch of the Notice of the AGM and holding shares as on the Cut-off Date (mentioned herein); (b) members who have forgotten the User ID and Password, can obtain / generate / retrieve the User ID and Password, has also been provided in the Notice of the AGM.

The remote e-voting facility will be available during the following voting period:
Commencement of remote e-voting : 1:00 p.m. IST on Sunday, June 14, 2026
End of remote e-voting : 5:00 p.m. IST on Thursday, June 18, 2026

The remote e-voting will not be allowed beyond the aforesaid date and time and the remote e-voting module shall be forthwith disabled by KFinTech upon expiry of the aforesaid period.

Members attending the AGM who have not cast vote(s) by remote e-voting will be able to vote electronically at the AGM ("Insta Poll").

Only a person, whose name is recorded as on the Cut-off Date, i.e., Friday, June 12, 2026, in the register of members / register of beneficial owners maintained by the Depositories, shall be entitled to avail the facility of remote e-voting or voting through Insta Poll.

Manner of registering / updating e-mail address:

a) Members holding shares in physical mode, who have not registered / updated their e-mail address with the Company, are requested to register / update their e-mail address by submitting Form ISR-1 (available on the website of the Company at www.ril.com) duly filled and signed along with requisite supporting documents to KFinTech at Unit: Reliance Industries Limited, Selenium Tower B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Hyderabad 500 032.

b) Members holding shares in dematerialised mode, who have not registered / updated their e-mail address with their Depository Participant(s), are requested to register / update their e-mail address with the Depository Participant(s) where they maintain their demat accounts.

In case of any query pertaining to e-voting, members may refer to the "Help" and "FAQs" sections / E-voting user manual available through a dropdown menu in the "Downloads" section of KFinTech's website for e-voting: <https://evoting.kfintech.com>.

Members are requested to note the following contact details for addressing queries / grievances relating to e-voting, if any:

Shri V. Balakrishnan, Vice President
KFin Technologies Limited
Unit: Reliance Industries Limited
Selenium Tower B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Hyderabad 500 032
E-mail: evoting.ril@kfintech.com
Toll-free No. 1800 309 4001 (from 9:00 a.m. (IST) to 6:00 p.m. (IST) on all working days)

Joining the AGM through VC / OAVM:

Members will be able to attend the AGM through VC / OAVM, through JioEvents, at <https://jioevents.jio.com/rilagm>. The information about login credentials to be used and the steps to be followed for attending the AGM are explained in Note no. 9 of the Notice of AGM. Members who have cast their vote(s) by remote e-voting may also attend the AGM but shall not be entitled to cast their vote(s) again at the AGM.

By order of the Board of Directors
Sd/-
Savithri Parekh
Company Secretary and Compliance Officer

Place : Mumbai
Dated : May 29, 2026

www.ril.com

RELAXO

RELAXO FOOTWEARS LIMITED

Regd. Office: Aggarwal City Square, Plot No. 10, Manglam Place, District Centre, Sector-3, Rohini, Delhi - 110085 (India), Phones: 91-11-46800600, 46800700, Fax No.: 91-11-46800692
E-mail: ril@relaxofootwear.com, Website: www.relaxofootwear.com
CIN: L74899DL1984PLC019097

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

| Particulars | Quarter Ended | | Year Ended | |
|--|---------------|------------|------------|------------|
| | 31.03.2026 | 31.03.2025 | 31.03.2026 | 31.03.2025 |
| | Audited | | | |
| 1. Total income from operations | 762.76 | 703.24 | 2748.36 | 2816.57 |
| 2. Net profit for the period before tax (before exceptional and extraordinary items) | 90.78 | 75.36 | 241.46 | 229.87 |
| 3. Net profit for the period before tax (after exceptional and extraordinary items) | 90.78 | 75.36 | 241.46 | 229.87 |
| 4. Net profit for the period after tax (after exceptional and extraordinary items) | 67.67 | 56.22 | 179.27 | 170.33 |
| 5. Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)] | 71.48 | 55.61 | 182.97 | 171.64 |
| 6. Equity share capital | 24.89 | 24.89 | 24.89 | 24.89 |
| 7. Reserves excluding revaluation reserve | - | - | 2181.47 | 2073.18 |
| 8. Earnings per equity share of face value of ₹ 1/- each (in ₹) | | | | |
| Basic | 2.72 | 2.26 | 7.20 | 6.84 |
| Diluted | 2.72 | 2.26 | 7.20 | 6.84 |

Note: The above is an extract of the detailed format of Quarterly/Annual Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Quarterly/Annual Audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.relaxofootwear.com. The same can also be accessed by scanning the QR Code provided below.



For and on behalf of the Board of Directors
Sd/-
Ramesh Kumar Dua
Chairman & Managing Director
DIN: 00157872



MY MUDRA
DIGITAL FINANCIAL SERVICES

Network of 160+ (approx.) Branches Providing both physical and digital financial services (phygital)

MY MUDRA FINCORP LIMITED
(Formerly Known as My Mudra Fincorp Private Limited)

(CIN: L65191DL2013PLC257611)
Registered Office: 17A/45, 2nd Floor, WEA, Karol Bagh, New Delhi - 110005, India
Website: www.mymudra.com | Email: info@mymudra.com | Tel.: 7291919151

India's NSE-Emerge Listed AI-Powered Fintech Redefining Lending with AI, Trust & Technology

My Mudra Fincorp Ltd has been officially certified under IRDA licensing as of June 11, 2025

My Mudra Fincorp Ltd has been officially certified by AMFI (Association of Mutual Funds in India) as of April, 2025

Revenue (Cr.)
46.01%

EBITDA
37.56%

PAT
33.22%

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2026

| S. No. | Particulars | Half year ended | | Year ended | |
|-------------|---|-----------------|--------------|--------------|--------------|
| | | Mar 31, 2026 | Sep 30, 2025 | Mar 31, 2025 | Mar 31, 2025 |
| | | (Audited) | (un-audited) | (Audited) | (Audited) |
| 1 | Total Income from Operations | 5,889.44 | 5,844.74 | 4,662.64 | 11,734.18 |
| 2 | Net Profit / (Loss) for the period before tax | 901.20 | 705.16 | 824.67 | 1,606.36 |
| 3 | Net Profit / (Loss) for the period after tax | 662.89 | 537.44 | 614.21 | 1,200.33 |
| 4 | Equity Share Capital | 1,139.18 | 1,139.18 | 1,139.18 | 1,139.18 |
| 5 | Reserves (including Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year | 5,402.40 | 4,719.51 | 4,202.07 | 5,402.40 |
| 6 | Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) | | | | |
| (a) Basic | 5.82 | 4.72 | 6.79 | 10.54 | 9.96 |
| (b) Diluted | 5.82 | 4.72 | 6.79 | 10.54 | 9.96 |

Notes:
1. The above is an extract of the detailed format of Audited Financial Results for the half year and year ended March 31, 2026 filed with the Stock Exchange(s) under Regulation 33 of the SEBI (LODR) Regulations, 2015.
2. The full format of the Audited Financial Results is available on the website of the Stock Exchange(s) at www.nseindia.com and on the Company's website at www.mymudra.com.
3. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 28, 2026.
4. The Statutory Auditors of the Company have issued Audit Report with unmodified opinion on the aforesaid financial results.

For and on behalf of the Board of Directors
Sd/-
Valishv Kishoretha
Chairman & Managing Director
DIN: 06979149

Date: 28.05.2026
Place: New Delhi